openPR Logo
Press release

Biosimilar Pipeline Analysis Market Estimated Growth Top Key Players Pfizer Inc., Novartis AG, Biocon, F. Hoffmann-La Roche Ltd, Amgen Inc., Kyowa Pharmaceutical Industry Co. Ltd, Boehringer Ingelheim GmbH, AstraZeneca

08-14-2019 08:29 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Biosimilar Pipeline Analysis

Biosimilar Pipeline Analysis

Biosimilar market is under the initial phase of development, they are used for the treatment of various disorders such as autoimmune disease, cancer as per National Institute of Health 2012 report, there were more than 23.5 million people living with autoimmune disease in the U.S. and low pricing of biosimilar drugs make them affordable for people. The same mechanism of action provides effective treatment for disease along with increased awareness among people are expected to fuel the growth of biosimilar pipeline market. Various companies and their R&D departments such as Pfizer Inc., Zydus Cadila are involved in the development of biosimilar, which is under clinical trial. Pfizer’s biosimilar clinical stage pipeline includes five monoclonal antibodies fare under clinical trial phase I and phase 3 which will be used for the treatment of autoimmune disease and oncology.

Request Sample Copy of this Research Report @ www.coherentmarketinsights.com/insight/request-sample/582

Biosimilar pipeline analysis market due to technological advancements in healthcare facilities and regulatory affiliation. Asia Pacific is expected to closely follow Europe in terms of growth due to increased prevalence of autoimmune disease, cancer, unmet clinical needs of people, and large price conscious population of emerging economies. North America market is expected to grow significantly due to high R&D investments, which supports the growth of biosimilar pipeline analysis market in near future.

There are various patented drugs available in the market, with certain drugs such as Adalimumab, the high cost of these drugs directed the biosimilar market. There are few drugs, which are under the last phase of clinical trial are BI695502 developed by Boehringer Ingelheim, PF- 06439535 by Pfizer, Biosimilar bevacizumab by Biocon, and FKB238 by Kyowa Pharmaceutical Industry Co. Increased R&D is expected to support the growth of biosimilar pipeline analysis market. There is a need for complex infrastructure in the development of biosimilar and lengthy process of clinical trial and approval are the major challenges faced by biosimilar pipeline analysis market.

There are various players present across the world and competing with each other extensively in the market to attain maximum share. Companies are also involved in R&D to increase the biosimilar pipeline. Some key players are Biocon, Pfizer Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Kyowa Pharmaceutical Industry Co. Ltd, Boehringer Ingelheim GmbH, AstraZeneca, Novartis AG, and Merck & Co.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/582

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Abhout US

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilar Pipeline Analysis Market Estimated Growth Top Key Players Pfizer Inc., Novartis AG, Biocon, F. Hoffmann-La Roche Ltd, Amgen Inc., Kyowa Pharmaceutical Industry Co. Ltd, Boehringer Ingelheim GmbH, AstraZeneca here

News-ID: 1822078 • Views:

More Releases from Coherent Market Insights

High End Greenhouse Market Exploration 2024 to 2031: Innovations, Key Players Data and Upcoming Opportunities |Texas Greenhouse Company Inc., Nexus Corporation
High End Greenhouse Market Exploration 2024 to 2031: Innovations, Key Players Da …
The global high end greenhouse market is estimated to surpass US$ 3,025.1 million by the end of 2030 in terms of revenue, exhibiting a CAGR of 5.2% during the forecast period (2023 to 2030). New Research Study High End Greenhouse Market 2024 Analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, and Investment Opportunities), Size, Share, and Outlook has been added to Coherent Market insight The High End Greenhouse Market research
Tattoo Accessories Market Insights Discussed Regarding Size, Share & Growth Opportunity | Major companies operating in the global tattoo accessories market are: Cheyenne
Tattoo Accessories Market Insights Discussed Regarding Size, Share & Growth Oppo …
New Research Study Tattoo Accessories Market 2024 Analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, and Investment Opportunities), Size, Share, and Outlook has been added to Coherent Market insight The Tattoo Accessories Market research report provides an analysis of major manufacturers, and geographic regions, and provides advanced information about the major challenges that will affect market growth. The report includes definition, classification, application and industrial chain structure, development trend, analysis
Adhesive Films Market Size and Share 2024-2031 Detailed Analysis by Company Profiles and Market Development Status |BASF SE, 3M, Ashland Inc., H.B. Fuller Company
Adhesive Films Market Size and Share 2024-2031 Detailed Analysis by Company Prof …
Global adhesive films market is projected to reach around US$ 25.37 Bn by 2030, in terms of revenue, exhibiting a CAGR of 5.8% during the forecast period (2023-2030). New Research Study Adhesive Films Market 2024 Analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, and Investment Opportunities), Size, Share, and Outlook has been added to Coherent Market insight The Adhesive Films Market research report provides an analysis of major manufacturers, and geographic
Safety Knives Market Demand Increasing and Industry Analysis in Upcoming Years by 2024-2031 |   Martor KG, Slice, Inc., The Safety Knife Company
Safety Knives Market Demand Increasing and Industry Analysis in Upcoming Years b …
New Research Study Safety Knives Market 2024 Analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, and Investment Opportunities), Size, Share, and Outlook has been added to Coherent Market insight The Safety Knives Market research report provides an analysis of major manufacturers, and geographic regions, and provides advanced information about the major challenges that will affect market growth. The report includes definition, classification, application and industrial chain structure, development trend, analysis

All 5 Releases


More Releases for Biosimilar

Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Interested to know more about the functioning of
Biosimilar Insulin Market Access
Boston, MA ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports. Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Prologue to Insulin Biosimilars 1.1 Outline Towards Insulin 1.2 Trail of Insulin Evolution and Development Rationale Design of Insulin Molecule 2.1 Structure of Insulin Polypeptide 2.2 Biosynthesis of Insulin 2.3 Secretion of Insulin Mechanism of Insulin in Diabetics 3.1 Glucose Metabolism of Insulin 3.2 Impact of Insulin Dysregulation in Diabetes 1 3.3 Impact
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.